Patents by Inventor Stefan Stutz

Stefan Stutz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND
    Publication number: 20240116900
    Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.
    Type: Application
    Filed: October 29, 2021
    Publication date: April 11, 2024
    Inventors: Simona COTESTA, Heng GE, Marc GERSPACHER, Catherine LEBLANC, Bo LIU, Edwige Liliane Jeanne LORTHIOIS, Rainer MACHAUER, Robert MAH, Tanja MEISTER, Christophe MURA, Pascal RIGOLLIER, Nadine SCHNEIDER, Stefan STUTZ, Andrea VAUPEL, Nicolas WARIN, Rainer WILCKEN, Lijun XUE, Marie-Anne LOZAC'H, Ross STRANG
  • PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES OF A KRAS G12C INHIBITOR FOR THE TREATMENT OF CANCERS
    Publication number: 20240082218
    Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.
    Type: Application
    Filed: December 20, 2021
    Publication date: March 14, 2024
    Inventors: Vasileios ASKOXYLAKIS, Saskia Maria BRACHMANN, Simona COTESTA, Xiaoming CUI, Jeffrey ENGELMAN, Anna FARAGO, Marc GERSPACHER, Diana GRAUS PORTA, Catherine LEBLANC, Edwige Liliane Jeanne LORTHIOIS, Bo LIU, Rainer MACHAUER, Robert MAH, Christophe MURA, Pascal RIGOLLIER, Nadine SCHNEIDER, Stefan STUTZ, Andrea Helga Emmi VAUPEL, Nicolas WARIN, Andreas WEISS, Rainer WILCKEN, Padmaja YERRAMILLI-RAO
  • Pyrazolyl derivatives useful as anti-cancer agents
    Patent number: 11702409
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: July 18, 2023
    Assignee: NOVARTIS AG
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • Pyrazolyl derivatives useful as anti-cancer agents
    Publication number: 20220363670
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 17, 2022
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • Pyrrolopyrrolidinone compounds
    Patent number: 9365576
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: June 14, 2016
    Assignee: Novartis AG
    Inventors: Simona Cotesta, Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
  • Substituted isoquinolinones and quinazolinones
    Patent number: 9051279
    Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: Joerg Berghausen, Nicole Buschmann, Pascal Furet, Francois Gessier, Joanna Hergovich Lisztwan, Philipp Holzer, Edgar Jacoby, Joerg Kallen, Keiichi Masuya, Carole Pissot Soldermann, Haixia Ren, Stefan Stutz
  • Pyrazolopyrrolidine compounds
    Patent number: 8969341
    Abstract: The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: March 3, 2015
    Assignee: Novartis AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
  • Pyrazolopyrrolidine Compounds
    Publication number: 20140350010
    Abstract: The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
  • IMIDAZOPYRROLIDINONE COMPOUNDS
    Publication number: 20140343084
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Application
    Filed: July 10, 2014
    Publication date: November 20, 2014
    Inventors: Pascal FURET, Vito GUAGNANO, Philipp HOLZER, Joerg KALLEN, Lv LIAO, Robert MAH, Liang MAO, Keiichi MASUYA, Achim SCHLAPBACH, Stefan STUTZ, Andrea VAUPEL
  • Cyclohexyl isoquinolinone compounds
    Patent number: 8859586
    Abstract: The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: October 14, 2014
    Assignee: Novartis AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Keiichi Masuya, Stefan Stutz
  • Hydroxy substituted isoquinolinone derivatives
    Patent number: 8859535
    Abstract: The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: October 14, 2014
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Pascal Furet, Philipp Holzer, Joerg Kallen, Keiichi Masuya, Stefan Stutz
  • CYCLOHEXYL ISOQUINOLINONE COMPOUNDS
    Publication number: 20140275158
    Abstract: The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Application
    Filed: June 19, 2012
    Publication date: September 18, 2014
    Applicant: Novartis AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Keiichi Masuya, Stefan Stutz
  • Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
    Patent number: 8815926
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: August 26, 2014
    Assignee: Novartis AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Lv Liao, Robert Mah, Liang Mao, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
  • HDYROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES
    Publication number: 20140135306
    Abstract: The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Application
    Filed: June 19, 2012
    Publication date: May 15, 2014
    Applicant: Novartis AG
    Inventors: Nicole Buschmann, Pascal Furet, Philipp Holzer, Joerg Kallen, Keiichi Masuya, Stefan Stutz
  • IMIDAZOPYRROLIDINONE COMPOUNDS
    Publication number: 20140011798
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Application
    Filed: January 24, 2013
    Publication date: January 9, 2014
    Applicant: NOVARTIS AG
    Inventors: Pascal FURET, Vito GUAGNANO, Philipp HOLZER, Joerg KALLEN, Lv LIAO, Robert MAH, Liang MAO, Keiichi MASUYA, Achim SCHLAPBACH, Stefan STUTZ, Andrea VAUPEL
  • FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS
    Publication number: 20130338152
    Abstract: The present invention provides a compound the invention, and its use as a IGF-1R inhibitor. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 8, 2012
    Publication date: December 19, 2013
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Bei Chen, Robin Alec Fairhurst, Songchun Jiang, Wenshuo Lu, Thomas H. Marsilje, III, Clive McCarthy, Pierre-Yves Michellys, Stefan Stutz
  • PYRROLOPYRROLIDINONE COMPOUNDS
    Publication number: 20130317024
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 28, 2013
    Applicant: NOVARTIS AG
    Inventors: Simona Cotesta, Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
  • SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES
    Publication number: 20130281473
    Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Application
    Filed: February 27, 2013
    Publication date: October 24, 2013
    Inventors: Joerg BERGHAUSEN, Nicole BUSCHMANN, Pascal FURET, Francois GESSIER, Joanna HERGOVICH LISZTWAN, Philipp HOLZER, Edgar JACOBY, Joerg KALLEN, Keiichi MASUYA, Carole PISSOT SOLDERMANN, Haixia REN, Stefan STUTZ
  • Substituted isoquinolinones and quinazolinones
    Patent number: 8440693
    Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: May 14, 2013
    Assignee: Novartis AG
    Inventors: Joerg Berghausen, Nicole Buschmann, Pascal Furet, François Gessier, Joanna Hergovich Lisztwan, Philipp Holzer, Edgar Jacoby, Joerg Kallen, Keiichi Masuya, Carole Pissot Soldermann, Haixia Ren, Stefan Stutz
  • 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
    Patent number: 8389526
    Abstract: The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: March 5, 2013
    Assignee: Novartis AG
    Inventors: Pascal Furet, Clive McCarthy, Joseph Schoepfer, Stefan Stutz